Duo-Blend CJC & Ipamorelin - Generic Peptides

Buy the Duo-Blend CJC and Ipamorelin 5 mg plus 5 mg vial by Generic Peptides at XSteroids. This is a fixed combination of two different growth hormone releasing peptides in one lyophilized vial: CJC-1295 without DAC, also called Mod GRF 1-29, and ipamorelin. They work through separate receptors, which is the whole point of the blend. This page explains each half, the mixed vial math, the practice of nightly injections and the anti-doping clause that covers both.

Two facts to hold on to: neither peptide is approved as a medicine, and no published study has tested this exact fixed combination. Everything below is built from the data on each component separately.

What the Duo-Blend Vial Contains and What You Are Buying

The vial holds 5 mg of CJC-1295 without DAC and 5 mg of ipamorelin, 10 mg of lyophilized powder in total. CJC-1295 without DAC is a modified form of growth hormone releasing hormone, GHRH(1-29), carrying four substitutions that protect it from the DPP-4 enzyme. Ipamorelin is a pentapeptide with the code NNC 26-0161 and the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2.

Both are supplied as one powder for a simple reason: they are injected at the same time, on the same empty stomach, and combining them removes one step from the protocol.

What arrives is a single glass vial holding 10 mg of total lyophilized powder, divided evenly at 5 mg of each peptide, with no diluent included: bacteriostatic water is ordered separately. It is one mixed vial rather than two separate products, and it is not a pre-mixed solution.

How CJC-1295 and Ipamorelin Work Together

The GHRH half

CJC-1295 without DAC binds the GHRH receptor on pituitary cells and primes them to release growth hormone. Because it has no drug affinity complex anchor, it does not bind albumin and its half-life stays short, around 30 minutes in review sources, which keeps the release pulse closer to the natural one. For comparison, the version with DAC is engineered for a half-life measured in days.

The ghrelin half

Ipamorelin works at the ghrelin receptor, a target distinct from the GHRH receptor; that receptor is also known as the growth hormone secretagogue receptor. Its human profile comes from healthy volunteers: the terminal half-life is close to two hours, the drug clears at roughly 0.078 litres per hour per kilogram of body weight, its volume of distribution at steady state is about 0.22 litres per kilogram, and growth hormone peaks 0.67 hours after the dose. The selectivity data are the interesting part: unlike GHRP-2 and GHRP-6, ipamorelin did not raise ACTH, cortisol or prolactin even at doses far above the effective range for growth hormone.

What has not been tested

The combination itself has no published clinical study. There is no data on how the two peptides behave when reconstituted in the same solution, and no head to head trial against injecting them separately. That is a real limitation of every blend product, this one included.

What to Expect from the Duo-Blend

Expect component-level data and no combination data. Ipamorelin was studied in healthy volunteers, where its terminal half-life was about two hours and it did not raise ACTH, cortisol or prolactin even at doses far above the effective range for growth hormone. CJC-1295 without DAC has no albumin anchor, so its half-life stays near 30 minutes, closer to the natural pulsatile release. What no study has tested is this exact fixed mixture: there is no data on the two peptides sharing one solution and no head-to-head trial against injecting them separately. Treat any claim about the blend itself as extrapolation from the two halves.

Duo-Blend Dose and Reconstitution

Mixing the 10 mg vial

With 2 ml of bacteriostatic water in the 10 mg vial, each peptide reaches 2.5 mg per ml, so 0.1 ml delivers 250 mcg of CJC-1295 and the same of ipamorelin, which is the 10-unit reading on a U-100 insulin syringe. Five millilitres lowers the strength to 1 mg per ml of each, so those 10 units then carry 100 mcg of each. With only 1 ml, the concentration is 5 mg per ml of each peptide and 4 units deliver 200 mcg of each. Swirl gently, never shake, and keep the vial cold.

Amounts discussed in research

Supplier write-ups usually describe 100 to 300 mcg of each peptide per injection, one to three times daily, most often before sleep, in blocks of eight to sixteen weeks followed by a break. At 200 mcg of each per day the 10 mg vial lasts 25 days. These figures are conventions from supplier material, not findings from a dose-finding trial, and no regulator has approved any amount.

Why CJC-1295 and Ipamorelin Are Combined

The pairing follows the biology. A GHRH analogue and a ghrelin receptor agonist act on two different receptors, and when both are stimulated the growth hormone pulse is larger than either alone, which is why researchers treat them as complements rather than substitutes. Night time dosing follows the natural rhythm, because the largest spontaneous growth hormone pulse of the day happens during deep sleep. Anyone who wants to compare options can look at CJC-1295 no DAC 5 mg on its own, Ipamorelin 5 mg on its own, the longer CJC-1295 DAC 5 mg, the GHRH analogue Sermorelin 5 mg, or the stronger secretagogues GHRP-2 10 mg and GHRP-6 10 mg, which do raise appetite. When the goal is a measured amount of hormone rather than a pituitary response, Somatropin 100 IU is the direct route.

Recovery and Cycle Breaks

Growth hormone releasing peptides leave the androgen axis alone, so no post-cycle therapy follows from using them. Recovery here means the break between blocks, and because both halves of this blend are short acting, the injection schedule rather than a long half-life does the work. Keeping injections on an empty stomach and avoiding food for a period afterwards is the practical rule repeated across supplier material; it is convention, not a trial result.

Duo-Blend Side Effects and Legal Status

Class level effects

Reviews of unregulated growth hormone peptides place fluid retention, joint and muscle soreness, reactions at the injection site, altered glucose handling and hormonal shifts among the class concerns. For ipamorelin itself, human profiling found that cortisol, prolactin and the remaining pituitary hormones did not rise, giving it the cleanest safety story of the secretagogues.

Regulatory and anti-doping status

Neither half is approved anywhere. The ipamorelin programme was halted when a phase II trial in postoperative ileus did not meet its efficacy endpoint, while CJC-1295 never won approval. Both are named in the WADA Prohibited List under class S2.2.4, growth hormone releasing factors, which applies at all times, in and out of competition.

General precautions

The material is supplied for laboratory work and is not medical advice. Secretagogues should not be used without clinical supervision by anyone who has a pituitary condition, cancer that is active, or diabetes. Keep the vial out of the reach of children, and never inject a cloudy solution.

Duo-Blend Storage and Stability

Keep the blended powder at 2 to 8 C and away from light, with a freezer reserved for months-long storage of the dry vial. After reconstitution the solution is held at 2 to 8 C and used within 28 to 30 days. Never freeze a mixed blend, and do not combine the two peptides drawn from separate vials in one syringe, because no compatibility data exist.

Why Buy Duo-Blend CJC & Ipamorelin from XSteroids?

Buying the Duo-Blend CJC and Ipamorelin vial from Generic Peptides at XSteroids means one 10 mg vial that covers both pathways, with the pack composition shown openly and a secure checkout. Shipping takes 3 to 6 days inside the US and 12 to 26 days abroad. We also state that the fixed combination has never been studied, which most blend sellers leave out.